GI Innovation products

Promotes the generation of cancer-specific effector T cell (Teff) in lymph nodes, and induces the activation and proliferation of tumor-infiltrating Teff and NK cells. Controls the immuno-suppressive function of regulatory T cells (Tregs) in tumor microenvironment (TME). Restores T cell function and anti-cancer immune responses in TME. Secures its safety in GLP toxicity study.

A novel long-acting lgE Trap-Fc fusion protein for allergic diseases; Broad therapeutic efficacy for IgE-mediated hypersensitivity reaction. Sufficient IgE control capacity for patients with high IgE levels. Low risk of anaphylactic shock and immunogenicity. High safety in GLP toxicity study.